Alcresta

About Alcresta

Alcresta Therapeutics, Inc. is a commercial-stage company based in Warren, New Jersey, specializing in the development and commercialization of enzyme-based products. The company’s primary focus is on addressing pancreatic insufficiency, a condition where the pancreas does not produce enough enzymes to properly digest food. Alcresta’s proprietary platform technology enables the creation of innovative products designed to help individuals with compromised pancreatic function and malabsorption issues.

One of Alcresta's flagship products is RELiZORB, an in-line digestive enzyme cartridge. This product is designed to mimic normal pancreatic function by breaking down fats in enteral tube feeding formulas. RELiZORB is approved for use in both pediatric patients aged 5 years and above and adult patients. The product has received a permanent and unique billing code from the Centers for Medicare and Medicaid Services (CMS), which facilitates reimbursement and expands patient access.

Alcresta operates in the healthcare market, specifically targeting patients with pancreatic insufficiency and related malabsorption conditions. Their clients include healthcare providers, hospitals, and patients who require specialized nutritional support. The company’s business model revolves around the development, approval, and commercialization of its enzyme-based products. Revenue is generated through the sale of these products, particularly RELiZORB, to healthcare providers and directly to patients.

In summary, Alcresta Therapeutics leverages its enzyme expertise to create novel solutions for individuals with pancreatic insufficiency, ensuring better nutrient absorption and overall health outcomes.